September 07, 2016
MEMPHIS, Tenn. & LYON, France–(BUSINESS WIRE)–In2Bones USA, LLC and In2Bones, SAS announced today that the two companies have completed a series of transactions which will combine, pursuant to an all-stock share exchange, In2Bones, SAS with its largest distributor, In2Bones USA, LLC.
The merger officially closed on August 31, 2016.The merged companies have become wholly-owned subsidiaries of a holding company known as In2Bones Global, Inc. (dba: i2b Global), creating a global company specializing in the fast-growing upper and lower extremities orthopaedic markets.
i2b Global will continue to operate both of its subsidiaries in Memphis, Tenn., and Lyon, France. The corporate headquarters for i2b Global will be based in Memphis.
“The two companies have shared a distribution and development relationship for several months. This merger allows us to better coordinate product development and distribution around the world,” says Alan Taylor, orthopaedic industry veteran and President and Chief Executive Officer of i2b Global.
“We have known for some time that we needed to combine the companies in order to add scale and efficiencies for our rapidly expanding enterprise,” says Eric Fourcault, a founder of In2Bones and head of the company’s Lyon, France and non-U.S. interests. “We believe this action will further accelerate our growth in the global market.”
About In2Bones USA, LLC
In2Bones USA, LLC is a designer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities. The company currently markets more than 12 products in the United States and has a product pipeline of 10 to 12 additional products slated for launch in the remainder of 2016 and 2017. For more information, visit www.i2b-USA.com.
About In2Bones, SAS
Located in Lyon, France, In2Bones, SAS is a specialty orthopaedic company that develops and distributes upper and lower extremity products to enable surgeons to alleviate pain and restore motion for their patients. For more information, visit www.In2Bones.com.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements reflect management’s current view of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “will,” and other similar terms. The company wishes to caution readers that actual results might differ materially from those described in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties impacting the business, including increased competition, technical obsolescence, regulatory issues, general economic conditions and other risks.
Susan Duensing, CBC